These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 16314219

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Approaches toward combining photodynamic therapy with pharmaceuticals that alter vascular microenvironment.
    Busch T.
    Retina; 2009 Jun; 29(6 Suppl):S36-8. PubMed ID: 19553798
    [Abstract] [Full Text] [Related]

  • 4. Guidance for the treatment of neovascular age-related macular degeneration.
    Schmidt-Erfurth UM, Richard G, Augustin A, Aylward WG, Bandello F, Corcòstegui B, Cunha-Vaz J, Gaudric A, Leys A, Schlingemann RO, European Society for Retina Specialists' Guidelines Committee (EURETINA).
    Acta Ophthalmol Scand; 2007 Aug; 85(5):486-94. PubMed ID: 17655610
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cardiovascular risk and antiangiogenic therapy for age-related macular degeneration.
    Tuñón J, Ruiz-Moreno JM, Martín-Ventura JL, Blanco-Colio LM, Lorenzo O, Egido J.
    Surv Ophthalmol; 2009 Aug; 54(3):339-48. PubMed ID: 19422962
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Current treatment of age-related macular degeneration.
    Zarbin M, Szirth B.
    Optom Vis Sci; 2007 Jul; 84(7):559-72. PubMed ID: 17632299
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients.
    Brown DM, Regillo CD.
    Am J Ophthalmol; 2007 Oct; 144(4):627-37. PubMed ID: 17893015
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration.
    Ferrara N, Damico L, Shams N, Lowman H, Kim R.
    Retina; 2006 Oct; 26(8):859-70. PubMed ID: 17031284
    [Abstract] [Full Text] [Related]

  • 18. Pegaptanib: new drug. In macular degeneration: too many risks for too little benefit.
    Prescrire Int; 2006 Aug; 15(84):127-9. PubMed ID: 16989023
    [Abstract] [Full Text] [Related]

  • 19. New therapies for neovascular age-related macular degeneration: critical appraisal of the current evidence.
    Virgili G, Do DV, Bressler NM, Menchini U.
    Acta Ophthalmol Scand; 2007 Feb; 85(1):6-20. PubMed ID: 17244204
    [Abstract] [Full Text] [Related]

  • 20. Pathology beyond neovascularization: new targets in age-related macular degeneration.
    Heier JS.
    Retina; 2009 Jun; 29(6 Suppl):S39-41. PubMed ID: 19553799
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.